AstraZeneca PLC (AZNl)

10,594.0
-96.0(-0.90%)
  • Volume:
    116,586
  • Bid/Ask:
    10,592.0/10,596.0
  • Day's Range:
    10,544.0 - 10,668.0
Earnings results expected in 9 days

AstraZeneca will announce its quarterly financial results in 9 days. Traders should take this into account as the share price often fluctuates around this time period.

AZNl Overview

Prev. Close
10,690
Day's Range
10,544-10,668
Revenue
25.02B
Open
10,620
52 wk Range
101.9-11,922.2
EPS
1.32
Volume
116,586
Market Cap
163.94B
Dividend (Yield)
221.70
(1.94%)
Average Volume (3m)
763,471
P/E Ratio
98.85
Beta
0.213
1-Year Change
22.48%
Shares Outstanding
1,549,800,030
Next Earnings Date
Feb 09, 2023
What is your sentiment on AstraZeneca?
or
Vote to see community's results!

AstraZeneca PLC News

AstraZeneca PLC Analysis

  • AZN Stock Under Pressure
    • ByTalkmarkets-

    Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses.

  • AstraZeneca’s Next “Wonder Drug”
    • ByTalkmarkets-

    Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential...

  • CinCor Pharma to be Acquired by AstraZeneca
    • ByTipRanks-

    WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which...

AstraZeneca PLC Company Profile

AstraZeneca PLC Company Profile

Employees
83100

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsSellSellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • Double top in reach
    0